AstraZeneca Q2 results lifted by sales of new drugs

In this article:

AstraZeneca raised its second quarter product sales forecast and had strong sales from its cancer medicines. Sales from its oncology unit shot up to $2.17 billion and the top-selling lung cancer drug nearly doubled to $784 million. Yahoo Finance’s Dan Roberts, Kristin Myers and Sibile Marcellus discuss today’s trending ticker.

Advertisement